- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02278406
Non-invasive Measurement of Brain Oxygen Levels in People With Subthalamic Deep Brain Stimulators
Employing Near Infrared Spectroscopy to Non-invasively Assess Changes in Cerebral Perfusion in Response to Subthalamic Deep Brain Stimulation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators will study the effects of electrical stimulation at the subthalamic nucleus on frontal cerebral perfusion in 10 patients with advanced PD who have already undergone successful STN DBS (Medtronic, Inc., Minneapolis, MN) surgery as evidenced by a 20% or greater improvement in their Unified Parkinson's disease rating scale (UPDRS) motor sub-score (UPDRS-III) with stimulation on vs off, three or more months after surgery. The UPDRS-III is a widely employed and validated rating scale of Parkinson's disease symptom severity that is based on the neurological examination. For the purposes of this study, a movement disorders neurologist will perform all of the neurological assessments. Patients must also be demonstrated to be cognitively intact as evidenced by a Montreal Cognitive Assessment (MoCA) Score of 24 or greater.
This is an experimental study in which we will compare frontal cerebral perfusion (measured non-invasively with the NIRS device) and UPDRS-III scores (as determined by neurological examination) in four clinical states: medications off/stimulation off; medication off/stimulation on; medication on/stimulation off; and medications on/stimulation on.
The primary question to be answered is: Can we detect significant changes in cerebral perfusion with the NIRS device in response to subthalamic stimulation delivered via implanted DBS devices?
This pilot study will be conducted in 10 PD patients who have undergone successful DBS surgery in the past. The study will be completed in one day as detailed below and will take about 6 hours to complete.
Patients will arrive to the movement disorders center on the morning of their scheduled study visit having discontinued their medications from the night before (12 hours 'off"). They will arrive with their stimulators on and set to the therapeutic parameters. Dr. Shih will perform a neurological examination and determine the UPDRS-III score in this, the off med/on stim state.
In order to perform the NIRS/perfusion measurements the subject will be fitted with a multipart plastic helmet, which holds a number of optical fibers against the surface of the subject's head. This helmet will be adjusted to fit comfortably. Additional probes will be positioned on the fingers in order to monitor peripheral blood oxygenation (i.e. pulse oximetry) to ensure that any changes observed in cerebral perfusion are due to changes in brain physiology, not a general physiological factor. The fibers are connected to 32 low power infrared laser diodes. The power emitted by these lasers is far below the typical maximum permissible exposure (MPE) level for skin exposure to a laser beam, as indicated by the American National Standards Institute, and subjects will not feel any effect from them. The laser light will be pointed at the top of their head, and there will be no risk to their eyes. The initial cerebral perfusion measurement will be made.
The patient's DBS devices will then be turned off and 60 min will be allowed to pass, allowing for washout of both the clinical and CBF effects of DBS. During this time, cerebral oxygenation will be monitored and documented every five minutes. At the end of this period the UPDRS-III score will be determined (off meds/off stim) and recorded, confirming a washout of the clinical effects. The DBS will then be turned on employing the settings employed for therapy except that the stimulation frequency will be set to 20Hz, a low frequency that is known not to be therapeutically effective in PD. All other settings will be maintained constant. Again, the cerebral oxygenation will be recorded every 5 min for 60 min after which the UPDRS-III score will be recorded The DBS will then be reprogrammed to the patient's steady state therapeutic settings, the cerebral oxygenation will be recorded every 5 min for 60 min, and at the end of the 60 min period the UPDRS-III score will be recorded again, completing the on stimulation/off medication evaluation. The patient will then be instructed to take his/her usual dose of medications, and will be sent for lunch for one hour. After lunch, the patient will return in the on medication/on stimulation state, the NIRS and pulse oximetry probes will be reapplied, and the process described for the off medication state will be repeated in the on medication state. After the on medication assessments are completed the patient will be sent home with his/her devices on and set to their therapeutic parameters.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-75
- Diagnosis of Idiopathic Parkinson's disease made by a movement disorders neurologist.
- At least 3 months status-post bilateral subthalamic deep brain stimulation surgery
- Positive response to STN DBS as evidenced by >20% improvement in UPDRS-III score after surgery as determined by a movement disorders neurologist.
- Cognitively intact as demonstrated with a MOCA > 24.
- Signed informed consent.
Exclusion Criteria:
- Failure to meet all of the inclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Parkinson's patients with DBS
Patients with Parkinson's Disease who are at least 3-months post subthalamic deep brain stimulator surgery
|
We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Brain oxygen levels
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013P000117
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
Clinical Trials on Deep brain stimulator
-
The University of Western AustraliaSir Charles Gairdner Hospital; Perron Institute for Neurological and Translational...WithdrawnTourette's SyndromeAustralia
-
Massachusetts General HospitalRecruitingEpilepsy | Obsessive Compulsive Disorder | Major Depressive DisorderUnited States
-
University of MiamiTerminatedParkinson's DiseaseUnited States
-
University Hospital, GrenobleTerminatedParkinson DiseaseFrance
-
Beijing Pins Medical Co., LtdBeijing Tiantan HospitalUnknownTreatment-Resistant Depression
-
University of FloridaCompleted
-
Beijing Pins Medical Co., LtdBeijing Tiantan HospitalUnknown
-
University of OxfordUnknown
-
Beijing Pins Medical Co., LtdCompleted
-
Nader PouratianMedtronicWithdrawn